GSK's depemokimab gets EMA nod for asthma and nasal polyps
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...
GSK's depemokimab under review in China and Japan for asthma, CRSwNP
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...
New cancer vaccine will 'stop disease before it takes hold'
The partnership between the pharmaceutical giant and the university aims to create a vaccine or vaccines which target cells ...
FiercePharma7h
Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
GlaxoSmithKline: Sell Rating Amidst Weak Vaccine Performance and Projected EPS Decline
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...
GlaxoSmithKline (GSK) Receives a Hold from Jefferies
Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
‘Shark’ pharmaceutical companies not being honest about side effects, MPs warned
MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...
Virginia Business2d
Pharma company to invest $54.2M in Richmond R&D facility
Listen to this article Pharmaceutical company Haleon will invest $54.2 million to upgrade its research and development facility in Richmond and launch an internship program in partnership with state ...